CBP issued updated Section 232 entry guidance for pharmaceutical articles and ingredients under Proclamation 11020.

A Section 232 measure is a U.S. trade action based on a finding that imports may affect national security. For pharmaceutical articles and ingredients, CBP entry guidance explains how importers should report covered goods and apply the treatment required by the applicable proclamation and official instructions. The guidance itself may clarify entry filing procedures without changing the underlying scope or legal requirements.

This type of measure typically affects manufacturers, distributors, wholesalers, and other importers bringing pharmaceuticals, active ingredients, or related materials into the United States. It matters because the product’s tariff classification, country of origin, form, and intended use can determine whether special Section 232 reporting or additional duties apply. Classification and scope decisions can be technical, so uncertain cases may require a customs broker or trade professional.

What to check

• Confirm the product’s complete tariff classification under the Harmonized Tariff Schedule, including any provisions specifically referenced by the official guidance.
• Review the measure’s scope carefully to determine whether the item is a pharmaceutical article, active ingredient, intermediate, or another covered product.
• Verify the product’s country of origin and distinguish it from the country of export or shipping location.
• Check the current CBP entry instructions for the required entry type, HTSUS reporting, documentation, and any applicable exclusions or exceptions.
• Ask a customs broker or trade counsel to review ambiguous formulations, mixtures, processing steps, or products that could fit more than one classification.